Lynn G. Dressler, Dr.P.H.
Affiliations: | 2003 | University of North Carolina, Chapel Hill, Chapel Hill, NC |
Area:
Public Health, Genetics, Neuroscience BiologyGoogle:
"Lynn Dressler"Cross-listing: PHTree
Parents
Sign in to add mentor| Thomas C. Ricketts | grad student | 2003 | UNC Chapel Hill | |
| (The need for uniform policy for the use of human specimens in genetic research.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Muss HB, Polley MC, Berry DA, et al. (2019) Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900647 |
| Dressler LG, Bell GC, Schuetze DP, et al. (2019) Implementing a personalized medicine cancer program in a community cancer system. Personalized Medicine |
| Muluneh B, Deal A, Alexander MD, et al. (2016) Patient perspectives on the barriers associated with medication adherence to oral chemotherapy. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners |
| Dressler LG, Deal AM, Owzar K, et al. (2015) Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance). Journal of the National Cancer Institute. 107 |
| Dressler LG, Deal AM, Patel J, et al. (2014) Cancer pharmacogenomics, adoption by oncologists and patient benefit. Personalized Medicine. 11: 143-153 |
| Dressler LG, Zeps N, Deal AM, et al. (2014) Return of individual research results: Policies and experiences of cancer genomic researchers. Journal of Clinical Oncology. 32: 11025-11025 |
| Dressler LG, Deal AM, Watson D, et al. (2013) Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials. Journal of Clinical Oncology. 31: 6501-6501 |
| Esserman LJ, Berry DA, DeMichele A, et al. (2012) Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3242-9 |
| Peppercorn J, Shapira I, Deshields T, et al. (2012) Ethical aspects of participation in the Database of Genotypes and Phenotypes of the National Center for Biotechnology Information: The Cancer and Leukemia Group B Experience Cancer. 118: 5060-5068 |
| Esserman LJ, Berry DA, Cheang MC, et al. (2012) Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment. 132: 1049-62 |